Candel Therapeutics’ (CADL) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Candel Therapeutics (NASDAQ:CADL) in a report released on Monday,Benzinga reports. They currently have a $11.00 target price on the stock. HC Wainwright also issued estimates for Candel Therapeutics’ Q4 2024 earnings at ($0.30) EPS, FY2024 earnings at ($1.65) EPS and FY2025 earnings at $0.15 EPS.

Candel Therapeutics Price Performance

Shares of CADL opened at $4.14 on Monday. Candel Therapeutics has a 52 week low of $0.77 and a 52 week high of $14.30. The company has a current ratio of 1.18, a quick ratio of 1.18 and a debt-to-equity ratio of 1.66. The firm has a market cap of $134.30 million, a price-to-earnings ratio of -2.39 and a beta of -0.88. The stock has a 50 day moving average of $5.86 and a 200-day moving average of $6.66.

Insider Buying and Selling at Candel Therapeutics

In other Candel Therapeutics news, major shareholder Estuardo Aguilar-Cordova sold 15,000 shares of Candel Therapeutics stock in a transaction that occurred on Monday, October 14th. The stock was sold at an average price of $6.02, for a total value of $90,300.00. Following the completion of the transaction, the insider now directly owns 929,873 shares in the company, valued at $5,597,835.46. The trade was a 1.59 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Insiders sold a total of 31,800 shares of company stock worth $193,380 over the last 90 days. Insiders own 41.60% of the company’s stock.

Institutional Trading of Candel Therapeutics

Several hedge funds have recently made changes to their positions in CADL. Point72 DIFC Ltd bought a new stake in Candel Therapeutics in the second quarter valued at $31,000. FMR LLC acquired a new stake in shares of Candel Therapeutics in the 3rd quarter worth about $46,000. MetLife Investment Management LLC bought a new stake in Candel Therapeutics in the 3rd quarter valued at about $87,000. Atom Investors LP acquired a new position in Candel Therapeutics during the 3rd quarter valued at about $103,000. Finally, Rhumbline Advisers bought a new position in Candel Therapeutics in the 2nd quarter worth about $143,000. Institutional investors own 13.93% of the company’s stock.

Candel Therapeutics Company Profile

Candel Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma.